Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).

@article{Schmidt2006IndomethacinPP,
  title={Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).},
  author={Barbara K Schmidt and R. S. Roberts and Avroy F Fanaroff and Peter G Davis and Haresh M Kirpalani and Chuks Nwaesei and Michael J. Vincer},
  journal={The Journal of pediatrics},
  year={2006},
  volume={148 6},
  pages={730-734}
}
OBJECTIVES To determine the risk of bronchopulmonary dysplasia (BPD) in subgroups of infants with and without patent ductus arteriosus (PDA) who were randomized to indomethacin prophylaxis or placebo, and to examine whether adverse drug effects on edema formation and oxygenation may explain why indomethacin prophylaxis does not reduce BPD. STUDY DESIGN We studied 999 extremely low birth weight infants who participated in the Trial of Indomethacin Prophylaxis in Preterms (TIPP) and who… CONTINUE READING